Canadian Cancer Trials Group Bulletins

General


Recent Publication

The Canadian Cancer Trials Group/AGITG CO.17 trial (A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma) demonstrated that cetuximab monotherapy improved overall and progression-free survival in patients previously treated for advanced colorectal cancer. A strong relationship was observed between benefit from cetuximab and development of rash. In this analysis, the association of rash and benefit from cetuximab is explored and presented by KRAS mutation status.

The authors concluded that as all patients with KRAS wild-type tumours benefitted to some extent from cetuximab regardless of the grade of rash, grade of rash was not a useful predictive marker.

Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the Canadian Cancer Trials Group/AGITG CO.17 (ONLINE). Acta Oncol 1-8, 2014.

http://informahealthcare.com/doi/abs/10.3109/0284186X.2013.879202